Antiangiogenic therapy in breast cancer.

Simon Peter Gampenrieder; Theresa Westphal; Richard Greil

doi:10.1007/s12254-017-0362-0

Antiangiogenic therapy in breast cancer.

Simon Peter Gampenrieder (First author), Theresa Westphal (Co-author), Richard Greil^* (Last author)

^*Corresponding author for this work

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Review article › peer-review

10 Citations (Web of Science)

Original language	English
Pages (from-to)	194-201
Journal	memo - Magazine of European Medical Oncology
Volume	10
Issue number	4
DOIs	https://doi.org/10.1007/s12254-017-0362-0
Publication status	Published - 2017

Keywords

PHASE-III TRIAL
ENDOTHELIAL GROWTH-FACTOR
BEVACIZUMAB-CONTAINING THERAPY
PACLITAXEL PLUS BEVACIZUMAB
TAXANE-BASED CHEMOTHERAPY
1ST-LINE TREATMENT
OPEN-LABEL
NEOADJUVANT CHEMOTHERAPY
ADJUVANT BEVACIZUMAB
2ND-LINE TREATMENT

Access to Document

10.1007/s12254-017-0362-0

Cite this

@article{590236003a944849bbce840d11a8c5bb,

title = "Antiangiogenic therapy in breast cancer.",

keywords = "PHASE-III TRIAL, ENDOTHELIAL GROWTH-FACTOR, BEVACIZUMAB-CONTAINING THERAPY, PACLITAXEL PLUS BEVACIZUMAB, TAXANE-BASED CHEMOTHERAPY, 1ST-LINE TREATMENT, OPEN-LABEL, NEOADJUVANT CHEMOTHERAPY, ADJUVANT BEVACIZUMAB, 2ND-LINE TREATMENT",

author = "Gampenrieder, {Simon Peter} and Theresa Westphal and Richard Greil",

note = "IIIrd Medical Department with Hematology and Medical Oncology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria",

year = "2017",

doi = "10.1007/s12254-017-0362-0",

language = "English",

volume = "10",

pages = "194--201",

journal = "memo - Magazine of European Medical Oncology",

issn = "1865-5041",

publisher = "Springer Verlag",

number = "4",

}

TY - JOUR

T1 - Antiangiogenic therapy in breast cancer.

AU - Gampenrieder, Simon Peter

AU - Westphal, Theresa

AU - Greil, Richard

N1 - IIIrd Medical Department with Hematology and Medical Oncology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria

PY - 2017

Y1 - 2017

KW - PHASE-III TRIAL

KW - ENDOTHELIAL GROWTH-FACTOR

KW - BEVACIZUMAB-CONTAINING THERAPY

KW - PACLITAXEL PLUS BEVACIZUMAB

KW - TAXANE-BASED CHEMOTHERAPY

KW - 1ST-LINE TREATMENT

KW - OPEN-LABEL

KW - NEOADJUVANT CHEMOTHERAPY

KW - ADJUVANT BEVACIZUMAB

KW - 2ND-LINE TREATMENT

U2 - 10.1007/s12254-017-0362-0

DO - 10.1007/s12254-017-0362-0

M3 - Review article

C2 - 29250196

SN - 1865-5041

VL - 10

SP - 194

EP - 201

JO - memo - Magazine of European Medical Oncology

JF - memo - Magazine of European Medical Oncology

IS - 4

ER -